Research Article
Prognostic Relevance of Nonsustained Ventricular Tachycardia in Patients with Pulmonary Hypertension
Table 1
Baseline characteristics.
| | | Patients without nsVT | Patients with nsVT | Significance | | | p |
| | Diagnosis (PH group 1/4) | 47/19 | 8/4 | 0.277 | | Age (years) | 60 ± 14.7
(Median: 60.5) | 66.6 ± 12.4
(Median: 66) | 0.112 | | Gender (female/male) | 50/16 | 8/4 | 0.277 | | PAH-specific medication (PDE5i/ERA/inh Prostanoid/CCB/Ima) | 28/7/0/5/2 | 5/2/0/1/0 | | | Combination therapy (dual/triple) | PDE5i + ERA = 15, | PDE5i + ERA = 2, | | | PDE5i + inh Prostanoid = 3, | PDE5i + inh Prostanoid = 2 | | PDE5i + ERA + inh Prostanoid = 4, | | PDE5i + Ima = 2 | | Antiarrhythmic medication (BB/Digoxin) | 11/1 | 1/0 | | Angiotensin-converting enzyme
inhibitors | 14 | 3 | | | Coronary heart disease | 8 | 2 | 0.274 | | Arterial hypertension | 28 | 7 | 0.238 | | Diabetes mellitus | 12 | 4 | 0.261 | | Cardiac pacemaker | 0 | 1 (indication: bradyarrhythmia) | |
|
|
BB: beta blocker; CCB: calcium channel blocker; ERA: endothelin receptor antagonist; Ima: imatinib; inh Prostanoid: inhaled Prostanoid; n: number; PDE5i: phosphodiesterase-5 inhibitor; PH: pulmonary hypertension; nsVT: nonsustained ventricular tachycardia.
|
